CORT
Corcept Therapeutics Incorporated
NASDAQ: CORT · HEALTHCARE · BIOTECHNOLOGY
$46.59
-0.06% today
Updated 2026-04-29
Market cap
$5.00B
P/E ratio
56.82
P/S ratio
6.57x
EPS (TTM)
$0.82
Dividend yield
—
52W range
$29 – $91
Volume
1.8M
WallStSmart proprietary scores
50
out of 100
Grade: C
Hold
Investment rating
6.0
Growth
B8.0
Quality
A6.0
Profitability
B5.0
Valuation
C+1/9
Piotroski F-Score
Weak
5.1
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →201 stocks currently score above 75
Price targets
Analyst target
$67.40
+44.67%
12-Month target
$24.55
-47.31%
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy3 Buy2 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Altman Z 5.08 — safe zone
+ Free cash flow $38.40M — positive
+ Revenue growth 11.10% QoQ
+ Debt/equity 0.01x — low leverage
Risks
- Piotroski 1/9 — weak financial health
- P/E 56.82x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $401.86M | $482.38M | $675.04M | $761.41M | $761.41M |
| Net income | $101.42M | $106.14M | $139.73M | $99.65M | $24.29M |
| EPS | — | — | — | — | $0.82 |
| Free cash flow | $119.91M | $126.90M | $195.90M | $141.78M | $38.40M |
| Profit margin | 25.24% | 22.00% | 20.70% | 13.09% | 13.10% |
Peer comparison
Smart narrative
Corcept Therapeutics Incorporated trades at $46.59. representing a P/E of 56.82x trailing earnings. Our Smart Value Score of 50/100 indicates the stock is fair. The company scores 1/9 on the Piotroski F-Score. With an Altman Z-Score of 5.08, it sits in the safe zone. TTM revenue stands at $761.41M. with profit margins at 13.10%.
Frequently asked questions
What is Corcept Therapeutics Incorporated's stock price?
Corcept Therapeutics Incorporated (CORT) trades at $46.59.
Is Corcept Therapeutics Incorporated overvalued?
Smart Value Score 50/100 (Grade C, Hold).
What is the price target of Corcept Therapeutics Incorporated (CORT)?
The analyst target price is $67.40, representing +44.7% upside from the current price of $46.59.
What is Corcept Therapeutics Incorporated's revenue?
TTM revenue is $761.41M.
Piotroski F-Score?
1/9 — weak financial health.
Altman Z-Score?
5.08 — safe zone.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio6.57x
ROE15.00%
Beta0.25
50D MA$38.84
200D MA$60.93
Shares out0.11B
Float0.09B
Short ratio—
Avg volume1.8M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—